Brüderkrankenhaus St. Josef Paderborn
- Address
- Husener Strasse 46, 33098 Paderborn, Germany
Brüderkrankenhaus St. Josef Paderborn - Oncology Research Center
Brüderkrankenhaus St. Josef Paderborn is an established clinical research center specializing in oncology and hematology with a focus on innovative treatment approaches for various cancers. The center actively participates in international multicenter trials, contributing to the advancement of cancer therapeutics through rigorous clinical investigation of novel drug combinations and targeted therapies.
- Metastatic colorectal cancer treatment strategies, including combination therapies with trifluridine/tipiracil
- Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML-CP) management
- Comparative efficacy studies of targeted therapies and tyrosine kinase inhibitors
The research facility demonstrates expertise in both solid tumor malignancies and hematologic cancers, conducting Phase II trials that evaluate treatment efficacy, tolerability, and safety profiles. Their participation in studies comparing monoclonal antibodies like panitumumab and bevacizumab, as well as novel targeted agents such as asciminib, reflects their commitment to identifying optimal first-line and front-line treatment regimens that improve patient outcomes while carefully assessing adverse event profiles.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Brüderkrankenhaus St. Josef Paderborn
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Tolerability and Efficacy of Asciminib Hydrochloride Versus Nilotinib in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase | Novartis Pharma AG | Phase III | Not Recruiting | Nov 2022 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Asciminib Hydrochloride | 1 | Unknown | 2022-11-21 | 2022-11-21 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.